SC
ABBV icon

Stephens Consulting’s AbbVie ABBV Stock Holding History

Stephens Consulting’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$334K Buy
1,464
+4
+0.3% +$911 0.11% 48
2025
Q3 		$338K Sell
1,460
-318
-18% -$64.8K 0.12% 46
2025
Q2 		$330K Sell
1,778
-45
-2% -$8.36K 0.08% 81
2025
Q1 		$382K Sell
1,823
-638
-26% -$124K 0.1% 66
2024
Q4 		$437K Buy
2,461
+723
+42% +$133K 0.11% 64
2024
Q3 		$343K Sell
1,738
-12
-0.7% -$2.24K 0.09% 74
2024
Q2 		$300K Buy
1,750
+24
+1% +$3.98K 0.09% 73
2024
Q1 		$314K Sell
1,726
-18
-1% -$3.1K 0.1% 68
2023
Q4 		$270K Sell
1,744
-32
-2% -$4.67K 0.09% 70
2023
Q3 		$265K Sell
1,776
-49
-3% -$7.19K 0.11% 63
2023
Q2 		$246K Sell
1,825
-18
-1% -$2.64K 0.1% 67
2023
Q1 		$294K Sell
1,843
-130
-7% -$19.9K 0.18% 61
2022
Q4 		$319K Sell
1,973
-122
-6% -$18.7K 0.21% 57
2022
Q3 		$281K Sell
2,095
-126
-6% -$18.1K 0.25% 56
2022
Q2 		$340K Sell
2,221
-24
-1% -$3.67K 0.28% 44
2022
Q1 		$364K Sell
2,245
-272
-11% -$39.5K 0.3% 49
2021
Q4 		$341K Buy
+2,517
New +$297K 0.28% 60

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Stephens Consulting's ABBV Position: Q4 2025 in Review

Stephens Consulting increased its AbbVie (ABBV) stake by 0.27% in Q4 2025, buying an estimated $911 and bringing the position to 1,464 shares worth $334K. The position accounts for 0.11% of the portfolio, ranked #48.

Stephens Consulting first reported a position in ABBV in Q4 2021 and has held it in 17 quarters since. The position peaked at $437K in Q4 2024. 4,160 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

  • Stephens Consulting held 1,464 shares of AbbVie worth $334K as of Q4 2025.
  • Stephens Consulting bought 4 AbbVie shares in Q4 2025, an estimated $911.
  • AbbVie made up 0.11% of Stephens Consulting's portfolio in Q4 2025, its #48 holding.
  • Stephens Consulting first reported a position in AbbVie in Q4 2021 and has held it in 17 quarters since.
  • Stephens Consulting's AbbVie position peaked at $437K in Q4 2024.
  • 4,160 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Stephens Consulting's 13F filing for Q4 2025, filed 13 Jan 2026.